Incyte (BSP:I1NC34) Days Payable

: 163.49 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Incyte's average Accounts Payable for the three months ended in Dec. 2023 was R$613 Mil. Incyte's Cost of Goods Sold for the three months ended in Dec. 2023 was R$342 Mil. Hence, Incyte's Days Payable for the three months ended in Dec. 2023 was 163.49.

The historical rank and industry rank for Incyte's Days Payable or its related term are showing as below:

BSP:I1NC34' s Days Payable Range Over the Past 10 Years
Min: 211.19 Med: 330.23 Max: 2646.61
Current: 211.19

During the past 13 years, Incyte's highest Days Payable was 2646.61. The lowest was 211.19. And the median was 330.23.

BSP:I1NC34's Days Payable is ranked better than
59.66% of 714 companies
in the Biotechnology industry
Industry Median: 149.875 vs BSP:I1NC34: 211.19

Incyte's Days Payable declined from Dec. 2022 (339.62) to Dec. 2023 (163.49). It may suggest that Incyte accelerated paying its suppliers.

Incyte Days Payable Historical Data

The historical data trend for Incyte's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

290.53

230.04

316.63

408.28

291.09

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															339.62	269.20	143.78	221.88	163.49

Competitive Comparison

For the Biotechnology subindustry, Incyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Days Payable distribution charts can be found below:

* The bar in red indicates where Incyte's Days Payable falls into.

Incyte Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Incyte's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1455.84	+	537.023)	/	2 )	/	1249.449	*	365
=	996.4315					/	1249.449	*	365
=	291.09

Incyte's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (688.509	+	537.023)	/	2 )	/	342.006	*	365 / 4
=	612.766					/	342.006	*	365 / 4
=	163.49

Incyte Days Payable Related Terms

Thank you for viewing the detailed overview of Incyte's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (BSP:I1NC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (BSP:I1NC34) Headlines

No Headlines